FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293559770> ?p ?o ?g. }

• W4293559770 endingPage "451" @default.
• W4293559770 startingPage "444" @default.
• W4293559770 abstract "ObjectiveAntithrombotic therapy is one of the cornerstones of the prevention of (recurrent) ocular or cerebral ischaemic events in patients with carotid artery stenosis. Randomised controlled trials on antithrombotic therapy for patients with minor ischaemic stroke and transient ischaemic attack (TIA) have recommended dual antiplatelet therapy (DAPT) in the three weeks following the index event. However, these trials excluded patients undergoing carotid revascularisation. To date, the optimal antithrombotic therapy during the peri-operative period of carotid endarterectomy (CEA) remains unclear.MethodsSymptomatic and asymptomatic patients with carotid artery stenosis undergoing primary CEA from the Dutch Audit for Carotid Interventions registry between June 2013 and December 2020 were eligible for inclusion. The primary outcome was defined as post-operative cervical bleeding needing re-intervention or intracranial haemorrhage during the first 30 days following CEA. The secondary outcomes were ischaemic stroke or TIA or all cause mortality during the first 30 days following CEA. Descriptive statistics and multiple logistic regressions analyses were applied, with acetylsalicylic acid (ASA) as the reference value.ResultsA total of 12 317 patients were included. In the peri-operative phase, 31.0% of patients were treated with ASA, 32.4% with clopidogrel, 11.1% with ASA plus clopidogrel, 10.4% with ASA plus dipyridamole, 10.3% with vitamin K antagonist, and 4.8% with direct acting oral anticoagulants therapy. After multiple logistic regression analysis, no association was seen with the primary outcome in ASA plus clopidogrel (odds ratio [OR] 0.81; confidence interval [CI] 0.58 – 1.13; p = .23), and ASA plus dipyridamole (OR 0.69; CI 0.47 – 1.00; p = .059). Both the DAPT therapies were not associated with the secondary outcome.ConclusionThe effectiveness and safety of DAPT did not differ from single antiplatelet therapy (SAPT) in patients undergoing CEA and further evaluation is needed in prospective studies. Considering additional data from the literature and guideline recommendations, DAPT should be started immediately after stroke until 30 days after CEA followed by SAPT, due to a possible reduction in the risk of recurrence. Antithrombotic therapy is one of the cornerstones of the prevention of (recurrent) ocular or cerebral ischaemic events in patients with carotid artery stenosis. Randomised controlled trials on antithrombotic therapy for patients with minor ischaemic stroke and transient ischaemic attack (TIA) have recommended dual antiplatelet therapy (DAPT) in the three weeks following the index event. However, these trials excluded patients undergoing carotid revascularisation. To date, the optimal antithrombotic therapy during the peri-operative period of carotid endarterectomy (CEA) remains unclear. Symptomatic and asymptomatic patients with carotid artery stenosis undergoing primary CEA from the Dutch Audit for Carotid Interventions registry between June 2013 and December 2020 were eligible for inclusion. The primary outcome was defined as post-operative cervical bleeding needing re-intervention or intracranial haemorrhage during the first 30 days following CEA. The secondary outcomes were ischaemic stroke or TIA or all cause mortality during the first 30 days following CEA. Descriptive statistics and multiple logistic regressions analyses were applied, with acetylsalicylic acid (ASA) as the reference value. A total of 12 317 patients were included. In the peri-operative phase, 31.0% of patients were treated with ASA, 32.4% with clopidogrel, 11.1% with ASA plus clopidogrel, 10.4% with ASA plus dipyridamole, 10.3% with vitamin K antagonist, and 4.8% with direct acting oral anticoagulants therapy. After multiple logistic regression analysis, no association was seen with the primary outcome in ASA plus clopidogrel (odds ratio [OR] 0.81; confidence interval [CI] 0.58 – 1.13; p = .23), and ASA plus dipyridamole (OR 0.69; CI 0.47 – 1.00; p = .059). Both the DAPT therapies were not associated with the secondary outcome. The effectiveness and safety of DAPT did not differ from single antiplatelet therapy (SAPT) in patients undergoing CEA and further evaluation is needed in prospective studies. Considering additional data from the literature and guideline recommendations, DAPT should be started immediately after stroke until 30 days after CEA followed by SAPT, due to a possible reduction in the risk of recurrence." @default.
• W4293559770 created "2022-08-30" @default.
• W4293559770 creator A5001648798 @default.
• W4293559770 creator A5029243600 @default.
• W4293559770 creator A5040056588 @default.
• W4293559770 creator A5044349788 @default.
• W4293559770 creator A5062454481 @default.
• W4293559770 date "2022-11-01" @default.
• W4293559770 modified "2023-10-14" @default.
• W4293559770 title "Editor's Choice – Risk of Bleeding Complications With Different Peri-Operative Antithrombotic Regimens During Carotid Endarterectomy: a National Registry Analysis" @default.
• W4293559770 cites W2081615170 @default.
• W4293559770 cites W2084280109 @default.
• W4293559770 cites W2105121618 @default.
• W4293559770 cites W2114775432 @default.
• W4293559770 cites W2163138223 @default.
• W4293559770 cites W2167077540 @default.
• W4293559770 cites W2206715408 @default.
• W4293559770 cites W2285459543 @default.
• W4293559770 cites W2548744167 @default.
• W4293559770 cites W2804570339 @default.
• W4293559770 cites W2884902425 @default.
• W4293559770 cites W2887589290 @default.
• W4293559770 cites W2899918508 @default.
• W4293559770 cites W2932189428 @default.
• W4293559770 cites W2964938334 @default.
• W4293559770 cites W2969448124 @default.
• W4293559770 cites W2971121646 @default.
• W4293559770 cites W2990240028 @default.
• W4293559770 cites W2999559585 @default.
• W4293559770 cites W3045683894 @default.
• W4293559770 cites W3107203539 @default.
• W4293559770 cites W3159575424 @default.
• W4293559770 cites W3164908038 @default.
• W4293559770 cites W3176433128 @default.
• W4293559770 cites W3184718141 @default.
• W4293559770 cites W4220820496 @default.
• W4293559770 cites W4280505765 @default.
• W4293559770 doi "https://doi.org/10.1016/j.ejvs.2022.08.020" @default.
• W4293559770 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36031046" @default.
• W4293559770 hasPublicationYear "2022" @default.
• W4293559770 type Work @default.
• W4293559770 citedByCount "3" @default.
• W4293559770 countsByYear W42935597702023 @default.
• W4293559770 crossrefType "journal-article" @default.
• W4293559770 hasAuthorship W4293559770A5001648798 @default.
• W4293559770 hasAuthorship W4293559770A5029243600 @default.
• W4293559770 hasAuthorship W4293559770A5040056588 @default.
• W4293559770 hasAuthorship W4293559770A5044349788 @default.
• W4293559770 hasAuthorship W4293559770A5062454481 @default.
• W4293559770 hasBestOaLocation W42935597701 @default.
• W4293559770 hasConcept C126322002 @default.
• W4293559770 hasConcept C127413603 @default.
• W4293559770 hasConcept C141071460 @default.
• W4293559770 hasConcept C156957248 @default.
• W4293559770 hasConcept C2776301958 @default.
• W4293559770 hasConcept C2776704044 @default.
• W4293559770 hasConcept C2776890861 @default.
• W4293559770 hasConcept C2777015399 @default.
• W4293559770 hasConcept C2777628954 @default.
• W4293559770 hasConcept C2777849778 @default.
• W4293559770 hasConcept C2779161974 @default.
• W4293559770 hasConcept C2779169563 @default.
• W4293559770 hasConcept C2779745121 @default.
• W4293559770 hasConcept C2780007028 @default.
• W4293559770 hasConcept C2780645631 @default.
• W4293559770 hasConcept C2781068581 @default.
• W4293559770 hasConcept C31174226 @default.
• W4293559770 hasConcept C71924100 @default.
• W4293559770 hasConcept C78519656 @default.
• W4293559770 hasConceptScore W4293559770C126322002 @default.
• W4293559770 hasConceptScore W4293559770C127413603 @default.
• W4293559770 hasConceptScore W4293559770C141071460 @default.
• W4293559770 hasConceptScore W4293559770C156957248 @default.
• W4293559770 hasConceptScore W4293559770C2776301958 @default.
• W4293559770 hasConceptScore W4293559770C2776704044 @default.
• W4293559770 hasConceptScore W4293559770C2776890861 @default.
• W4293559770 hasConceptScore W4293559770C2777015399 @default.
• W4293559770 hasConceptScore W4293559770C2777628954 @default.
• W4293559770 hasConceptScore W4293559770C2777849778 @default.
• W4293559770 hasConceptScore W4293559770C2779161974 @default.
• W4293559770 hasConceptScore W4293559770C2779169563 @default.
• W4293559770 hasConceptScore W4293559770C2779745121 @default.
• W4293559770 hasConceptScore W4293559770C2780007028 @default.
• W4293559770 hasConceptScore W4293559770C2780645631 @default.
• W4293559770 hasConceptScore W4293559770C2781068581 @default.
• W4293559770 hasConceptScore W4293559770C31174226 @default.
• W4293559770 hasConceptScore W4293559770C71924100 @default.
• W4293559770 hasConceptScore W4293559770C78519656 @default.
• W4293559770 hasIssue "5" @default.
• W4293559770 hasLocation W42935597701 @default.
• W4293559770 hasLocation W42935597702 @default.
• W4293559770 hasOpenAccess W4293559770 @default.
• W4293559770 hasPrimaryLocation W42935597701 @default.
• W4293559770 hasRelatedWork W1410456685 @default.
• W4293559770 hasRelatedWork W2071639342 @default.
• W4293559770 hasRelatedWork W2078657247 @default.
• W4293559770 hasRelatedWork W2088221491 @default.
• W4293559770 hasRelatedWork W2125320805 @default.

• next